Technology | April 22, 2009

Corventis Launches AVIVO Mobile Patient Management System

April 22, 2009 - Corventis Inc. this week released a non-invasive, wireless cardiac monitor system, AVIVO Mobile Patient Management System for the detection of arrhythmias.

The system received FDA clearance and is now commercially available in the U.S. The company’s PiiX wearable sensor enables continuous monitoring for ambulatory patients, providing clinicians with insight into patient cardiovascular health during normal daily routines. The PiiX sensor automatically collects physiological information and wirelessly transmits the data from the patient to Corventis for further analysis and presentation on a secure Web site.

The system provides clinicians actionable information on an exception basis to help diagnose potential health risks, including non-lethal arrhythmias, from anywhere.

The company said the device offers a range of information that was previously only possible through an implantable cardiac monitor.

“This is an example of how non-invasive wireless technology has the potential to markedly transform the way we monitor patients on a continuous and remote basis,” said Eric J. Topol, M.D., director of the Scripps Translational Science Institute and chief academic officer of Scripps Health.

“The Corventis technology platform has the potential to transform arrhythmia monitoring for both patients at home and eventually, hospitalized patients,” said Leslie Saxon, M.D., chief, division of cardiology, Keck School of Medicine at the University of Southern California, Los Angeles. “The freedom of movement and timely arrhythmia detection will create a comfortable environment for all patients. We’ve learned that networked devices that can provide nearly instantaneous diagnosis, treatment and reassurance to patients answer one of the greatest needs in medicine today.”

Cardiac arrhythmias can cause chest pain and fainting, and some lethal arrhythmias can lead to sudden cardiac death. More than two million Americans have atrial fibrillation, a type of cardiac arrhythmia that is associated with an increased risk for stroke. 835,000 Americans are discharged from hospital care with cardiac arrhythmia diagnoses each year.

“The range of physiological information made available and the ease with which that information is collected and reviewed is one of the most exciting aspects of the Corventis platform,” said Inder Anand, M.D., Ph.D., director of the Heart Failure Program, Minneapolis V.A. Medical Center and professor of medicine, University of Minnesota, MN. “By carefully evaluating changes in physiological status identified with a Corventis solution, cardiologists may soon have a tool to proactively manage heart failure patients and reduce re-hospitalizations.”

For more information:

Related Content

Cardea Solo Wearable ECG Collects High-Altitude Cardiac Data on Denali Expedition

David R. Ohlson, DO (right), logs patient cardiac information and labels a used Cardea Solo ECG sensor while USX climber Adam Storck (left) replaces his sensor at Denali's 14,200-foot camp. Photo courtesy of Ron Oliver, USX.

News | ECG Wireless Remote Access | August 24, 2018
U.S. Expeditions and Explorations (USX) and Cardiac Insight Inc. announced the successful completion of an expedition...
Overlay Init